Form 4: Aptevo Therapeutics Director Acquires Restricted Stock Units
SEC Form 4 Filing
Director John Niederhuber acquired 925 Restricted Stock Units (RSUs) of Aptevo Therapeutics Inc. on July 17, 2024, which vest in full on the first anniversary of the grant date.
Summary
- On July 17, 2024, John Niederhuber, a director of Aptevo Therapeutics Inc., acquired 925 Restricted Stock Units (RSUs).
- These RSUs convert into common stock on a one-for-one basis.
- The RSUs will vest in full on the first anniversary of the grant date.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Positives
- The acquisition of RSUs by a director may signal confidence in the company's future prospects.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Stakeholder Impact
- Shareholders are informed about the director's acquisition of RSUs, providing transparency into insider activity.
Key Dates
| Date | Description |
|---|---|
| 07/17/2024 | Date of transaction: John Niederhuber acquired 925 Restricted Stock Units. |
| 07/17/2025 | RSUs vest in full on the first anniversary of the date of grant. |
| 07/19/2024 | Date of signature of the report. |
Keywords
Aptevo Therapeutics, Director, RSU, Restricted Stock Units, Beneficial Ownership, Form 4, Niederhuber, Equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.